Abstract Details

Title Continuous Objective Monitoring in Parkinson’s Disease: A description of over 25,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG) wearable monitoring device

Topic Movement Disorders

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-003

Objective

The objective of this population study was to update & describe the objective symptom scores from a large, deidentified PKG database of PD patients.

Background The Personal KinetiGraph™ (PKG™) Movement Recording System is a wearable medical device that provides continuous, objective, ambulatory movement data during routine daily activities and provides information on medication compliance, motor fluctuations, immobility, and tremor for patients with Parkinson’s disease (PD). Recent evidence has also proposed targets for treatable symptoms.

Design/Methods

27,834 complete and deidentified PKGs from Jan 2012 to August 2018 used globally for routine clinical care were included. Incomplete records were excluded. Median scores for bradykinesia (BKS) & dyskinesia (DKS) as well as percent time with tremor (PTT) and percent time immobile (PTI) were included as well as proportions of PKGs above published PKG summary score target values (BKS >25, DKS>9, PTT>1%, PTI>10%). Two sub-analyses included subjects who had 2+ PKG records & scores above proposed BKS & DKS targets on their first PKG. The Kruskal-Wallis & paired t tests were used for analysis.

Results

Global median PKG score & percent of scores above published targets were summarized. Overall, 54% of BKS scores were >25 & ranged from 46% to 61% by country. 10% of all DKS scores were >9 & ranged from 5%-15% by country. Subanalyses of global median BKS & DKS scores across subsequent PKGs showed significant improvements in BKS & DKS from 1^st to subsequent PKGs (all p<0.05).

Conclusions A meaningful proportion of patients have sub-optimal PD motor symptoms. Elevated & likely treatable BKS & DKS symptom scores improved in subsequent PKGs without notable increases in respective DKS or BKS. Continuous objective monitoring (COM) in PD enables quantification of PD motor symptoms, which can enhance clinical decision making, track symptoms over time, & improve PD symptom scores.

Authors/Disclosures
Peter Lynch (GKC) PRESENTER	No disclosure on file
Rajesh Pahwa, MD, FAAN (University of Kansas Medical Center)	Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ACADIA. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Insightec. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jaaz. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fasikl. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Photopharmics. The institution of Dr. Pahwa has received research support from Abbott. The institution of Dr. Pahwa has received research support from Abbvie. The institution of Dr. Pahwa has received research support from Biogen. The institution of Dr. Pahwa has received research support from Parkinson Foundation. The institution of Dr. Pahwa has received research support from Roche. The institution of Dr. Pahwa has received research support from Sage. The institution of Dr. Pahwa has received research support from Sun Pharma. The institution of Dr. Pahwa has received research support from Theravance. The institution of Dr. Pahwa has received research support from Neuroderm. The institution of Dr. Pahwa has received research support from Ask Bio. The institution of Dr. Pahwa has received research support from Blue Rock. The institution of Dr. Pahwa has received research support from Cerevance. The institution of Dr. Pahwa has received research support from Fasikl. The institution of Dr. Pahwa has received research support from Scion. The institution of Dr. Pahwa has received research support from UCB. The institution of Dr. Pahwa has received research support from Ono. The institution of Dr. Pahwa has received research support from Intra-cellular Therapies. The institution of Dr. Pahwa has received research support from Ask Bio. The institution of Dr. Pahwa has received research support from Michael J Fox Foundation . The institution of Dr. Pahwa has received research support from Neuron 23. The institution of Dr. Pahwa has received research support from Roche.
Filip Bergquist	The institution of Filip Bergquist has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Filip Bergquist has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Arvid Carlsson Research AB. The institution of Filip Bergquist has received research support from Swedish Government. The institution of Filip Bergquist has received research support from Parkinsonfonden. The institution of Filip Bergquist has received research support from Neuro Sweden. The institution of Filip Bergquist has received research support from Swedish Research Council. Filip Bergquist has received publishing royalties from a publication relating to health care. Filip Bergquist has received publishing royalties from a publication relating to health care. Filip Bergquist has a non-compensated relationship as a Advisor with Sense4Care that is relevant to AAN interests or activities.
Malcolm Horne	No disclosure on file

��ɫ��

��ɫ��